Shailen Singh

Shailen Singh is an experienced executive in the biotechnology and pharmaceutical sectors, currently serving as Executive Director and Global Head of Biologics & Vaccines Commercialization Technology Transfer at Merck since 2016. Singh is responsible for overseeing technology transfers for biologics and vaccines to commercial manufacturing sites, both internal and external, on a global scale. Previously, as Executive Director of Global Vaccines & Biologics Commercialization, accountability included commercialization, technology development, and life cycle management in a commercial cGMP environment. Other roles at Merck include Director of Biologics Process Development & Commercialization. Prior to Merck, Singh held various positions at AstraZeneca, culminating in the role of Principal Scientist, and currently serves on the Board of the ACLU of Delaware. Academic qualifications include a Bachelor's and Master's degree in Biochemical Engineering & Biotechnology from the Indian Institute of Technology, Delhi, a PhD in Chemical Engineering/Cell Molecular Biology from the University of California, Riverside, and executive education from Duke University and MIT Sloan.